Please login to the form below

Not currently logged in

DNA damage specialists Artios Pharma raises $84m


Team behind development of Lynparza focus on next-gen DDR inhibitors

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

Regeneron and Bluebird sign $100m cell therapies deal

regeneron headquartersSix targets chosen from TCR and other cell therapy platforms

Mallinckrodt doses first patient in muscular dystrophy trial

MallinckrodtRepurposed drug could help delay decline in muscle function

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

Nanobiotix signs €40m deal with the EIB

Nanobiotixloan to fund innovative nanomedicine platform

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Biogen Idec buildingMixed results prompted a 10% share drop for both companies

GSK two-drug trial in untreated HIV raises Gilead rivalry

ViiV HealthcareIntends to file the combination later this year to challenge Gilead’s Biktarvy

Celgene’s Revlimid gets a win in late-stage lymphoma

Celgene buildingPatients on Revlimid and Roche’s Rituxan saw boosted PFS rates

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
How Helpful are Simple Health Messages?